2026-01-15 - Analysis Report
**English Report**

**Company Overview:**
AbbVie Inc is a biopharmaceutical company.

**Return Rate Comparison:**
- Review stock: AbbVie Inc (ABBV)
  * Rate: 181.42%
- Comparison stock: S&P 500 (VOO)
  * Rate: 93.94%
  * Degree of divergence (last day of data): 87.50
  * Relative divergence: 69.20%

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | $163.2B |
| 2017-2019  | 42.0% | 21.6% | 25.0% | 1.1 | $156.8B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | $189.7B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | $239.7B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | $286.1B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | $274.4B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | $314.6B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | $404.6B |

**Recent Stock Price Fluctuations:**

|  | Price |
| --- | --- |
| Close | $220.75 |
| Last-market | $221.21 |
| Price change | $0.21 |
| 5-day SMA | $223.68 |
| 20-day SMA | $226.13 |
| 60-day SMA | $226.47 |

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence:**

- Market Risk Indicator (MRI) = 0.70
- RSI = 41.59
- PPO = -0.38
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium
- Recent (20 days) relative divergence change = -3.00
- 7-day Rank change = 0
- 7-day Dynamic Expected Return change = 0.00
- Expected Return (%) = 36.20%

**Recent News and Significant Events:**

* Representative Julia Letlow Just Disclosed New Stock Trades
* BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View
* AbbVie partners with China's RemeGen on experimental tumor treatment
* Is AbbVie a Buy, Sell, or Hold in 2026?
* AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
* Is AbbVie (ABBV) Pricing Look Attractive After Strong Multi Year Share Gains

**Analyst Opinions:**

Analytical Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): $244.59 / $289.00 / $184.00

**Comprehensive Analysis (Summary of previous items, including news):**
AbbVie Inc (ABBV) stock has shown significant return rate compared to the S&P 500 (VOO). The company's Alpha, Beta analysis shows mixed results across different periods. The stock price has fluctuated in the recent months, with moving averages indicating a potential increase. The RSI and PPO index indicators indicate a moderate risk level and a sell signal. The expected return is 36.20%. Recent news and events, including a partnership with China's RemeGen, may impact the stock price. Analysts agree on a buy recommendation with a target price range of $244.59 to $289.00.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.